Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -775.59% is 1040% below its 4-year average of -68.01%, near the low end of its 4-year range (-775.59%–-29.07%).
As of the fiscal period ended Tuesday, June 30, 2026. 169.85% below its 12-month average of -287.42%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -775.59%.
RETURN ON EQUITY (ROE)
-775.59%
RETURN ON EQUITY (ROE) AVG TTM
-287.42%
RETURN ON EQUITY (ROE) AVG 3Y
-93.05%
RETURN ON EQUITY (ROE) AVG 5Y
-68.01%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-169.85%
CURRENT VS 3Y AVG
-733.49%
CURRENT VS 5Y AVG
-1040.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-1746.19%
vs the sector median at left
Pyxis Oncology, Inc.
Market Cap
$127.98M
Return on Equity (ROE)
-775.59%
TTM Avg
-287.42%
3Y Avg
-93.05%
5Y Avg
-68.01%
Market Cap
$127.29M
Return on Equity (ROE)
N/A
TTM Avg
143.89%
3Y Avg
2.05%
5Y Avg
-53.47%
Market Cap
$130.79M
Return on Equity (ROE)
-262.64%
TTM Avg
-45.72%
3Y Avg
-38.99%
5Y Avg
-37.83%
Market Cap
$131.21M
Return on Equity (ROE)
-11.20%
TTM Avg
-11.86%
3Y Avg
-12.45%
5Y Avg
-5.17%
Market Cap
$124.70M
Return on Equity (ROE)
-234.42%
TTM Avg
-102.69%
3Y Avg
-100.55%
5Y Avg
-100.92%
Market Cap
$124.18M
Return on Equity (ROE)
-165.57%
TTM Avg
-146.09%
3Y Avg
30.63%
5Y Avg
465.14%
Market Cap
$132.03M
Return on Equity (ROE)
-266.86%
TTM Avg
156.76%
3Y Avg
98.17%
5Y Avg
-694.29%
Market Cap
$122.66M
Return on Equity (ROE)
-71.83%
TTM Avg
-71.89%
3Y Avg
-76.88%
5Y Avg
-67.88%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | $127.98M | -775.59% | -287.42% | -93.05% | -68.01% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.29M | N/A | 143.89% | 2.05% | -53.47% |
| Health Catalyst, Inc. (HCAT)vs › | $130.79M | -262.64% | -45.72% | -38.99% | -37.83% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $131.21M | -11.20% | -11.86% | -12.45% | -5.17% |
| Entera Bio Ltd. (ENTX)vs › | $124.70M | -234.42% | -102.69% | -100.55% | -100.92% |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.18M | -165.57% | -146.09% | 30.63% | 465.14% |
| LifeMD, Inc. (LFMD)vs › | $132.03M | -266.86% | 156.76% | 98.17% | -694.29% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | -71.83% | -71.89% | -76.88% | -67.88% |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $122.43M | -5.10% | -4.24% | -6.16% | 0.09% |
ROE
-775.6%
ROA
-161.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -775.59% |
| 2026-03-31 | -261.40% |
| 2025-12-31 | -149.08% |
| 2025-09-30 | -141.16% |
| 2025-06-30 | -109.86% |
| 2025-03-31 | -92.37% |
| 2024-12-31 | -64.04% |
| 2024-09-30 | -37.32% |
| 2024-06-30 | -34.87% |
| 2024-03-31 | -31.39% |
| 2023-12-31 | -58.70% |
| 2023-09-30 | -68.36% |
| 2023-06-30 | -68.09% |
| 2023-03-31 | -71.36% |
| 2022-12-31 | -75.06% |
| 2022-09-30 | -53.75% |
| 2022-06-30 | -41.49% |
| 2022-03-31 | -30.20% |
| 2021-12-31 | -29.07% |
| 2021-03-31 | -748.36% |
